Skip to main content
v2026.11,986 entries · CC-BY 4.0
LAC HealthSponsored

Shop cranial helmet supplies

  • FDA registered
  • ISO 13485
  • BBB Accredited A+

Shop at LAC Health

Cranial Helmet: FDA Class, Indications and Evidence

A cranial helmet is an FDA Class II, prescription-only cranial orthosis for infants aged 3 to 18 months. See the regulation, evidence and payer criteria.

Written and maintained by CASRAI Editorial Board

Published · Last updated

On this page

A cranial helmet is a cranial orthosis: a prescription-only, FDA Class II device that applies pressure to prominent regions of an infant’s head to improve cranial symmetry or shape. Under 21 CFR 882.5970 it is indicated for infants aged 3 to 18 months with moderate to severe nonsynostotic positional plagiocephaly. The evidence for it is contested, and payer rules differ from the regulatory indication.

General information for clinic, laboratory and supply staff. This is not medical advice and does not describe fitting or treatment; decisions about an individual infant belong with that infant’s clinician.

Definition and scope

US federal regulation names the device a cranial orthosis. 21 CFR 882.5970(a) identifies it as a device intended for medical purposes to apply pressure to prominent regions of an infant’s cranium in order to improve cranial symmetry and/or shape in infants from 3 to 18 months of age, with moderate to severe nonsynostotic positional plagiocephaly, including infants with plagiocephalic-, brachycephalic- and scaphocephalic-shaped heads. “Cranial helmet” and “cranial remolding orthosis” are everyday and billing names for the same product category.

Three terms matter for reading the regulation and the research:

  • Positional (nonsynostotic) plagiocephaly: a skull shape change caused by positioning, not by early closure of a cranial suture.
  • Posterior plagiocephaly: unilateral parieto-occipital flattening.
  • Brachycephaly: symmetric flattening of the back of the head (terms as defined in the Congress of Neurological Surgeons guideline).

It is not a protective sports or safety helmet, and it is not an over-the-counter product. The regulation classifies it as a prescription device. For the wider device framework see what a medical device is.

How it is regulated and used in practice

The classification record is specific. 21 CFR 882.5970(b) places the device in Class II (special controls). The special controls named in the regulation are prescription use in accordance with 21 CFR 801.109, biocompatibility testing, and labeling covering contraindications, warnings, precautions, adverse events, and instructions for physicians and parents. The regulation’s source note is 63 FR 40651 (July 30, 1998).

The openFDA device classification database lists two product codes under this regulation, both Class II, both in the Neurology review panel and not exempt from good manufacturing practice requirements:

Product code Name in FDA database Note
MVA Orthosis, Cranial The base product code.
OAN Orthosis, Cranial, Laser Scan Definition adds that a laser scanning accessory may be used to create a scan of the infant’s head.

Because it is a Class II device, new products normally reach the US market through 510(k) premarket notification; the broader pathway map is in FDA device classification, 510(k) and PMA. The biocompatibility special control corresponds to the ISO 10993 framework explained in FDA guidance on biocompatibility.

What the clinical evidence says

The Congress of Neurological Surgeons evidence-based guideline on cranial molding orthosis therapy for positional plagiocephaly (Tamber et al., 2016, endorsed by the AANS/CNS Joint Guidelines Committee and the American Academy of Pediatrics) reviewed 15 studies: one prospective randomized trial, five prospective comparative studies and nine retrospective comparative studies. It states plainly that there is no standard treatment for positional plagiocephaly; the options are observation, repositioning, physical therapy, helmet therapy, and, rarely, surgery.

  • Guideline grading: the guideline graded its helmet-therapy recommendations at Level II, the middle of its three evidence levels, and all 15 included studies were Class II quality evidence.
  • The contrary trial: the single randomized trial concluded that helmet therapy had no added value in moderate to severe positional plagiocephaly, and all parents of helmeted infants reported one or more side effects. The guideline notes that this result stands in stark contrast to the remaining evidence and that the groups were imbalanced at baseline.
  • What remains open: the guideline concludes that there is a fairly substantive body of non-randomized evidence showing faster and greater improvement in cranial shape with a helmet than with conservative therapy, but that specific criteria for measuring deformity and the best timing window remain elusive.

Criteria crosswalk: regulation and one payer policy

A regulation and a payer policy answer different questions, which is why they do not line up. The table compares what each one says; the payer column is a single plan’s policy, not a statement about all payers.

Criterion 21 CFR 882.5970 (FDA) Geisinger Health Plan policy MP125
Age window 3 to 18 months Under 18 months; older than 18 months not covered (“insufficient evidence”)
Severity Moderate to severe nonsynostotic positional plagiocephaly Considered unlikely to respond to repositioning or physical therapy because of severity, generally 2 standard deviations or more from the mean cranial index for age and gender
Prior conservative trial Not part of the device identification No response to a two-month trial of repositioning (or a 2-month physical therapy trial where clinically appropriate, such as congenital torticollis)
Prescription Required (801.109) Medical-necessity review; coverage subject to the plan’s benefit documents
Exclusions Indication limited to nonsynostotic plagiocephaly Head deformities from uncorrected craniosynostosis or hydrocephalus not covered

The Geisinger policy defines cranial index as head width divided by length times 100, with 76 to 90 percent considered normocephalic. It lists HCPCS code S1040, “Cranial remolding orthosis, pediatric, rigid, with soft interface material, custom fabricated, includes fitting and adjustment(s).”

Where it matters for labs, clinics and supply decisions

  • Documentation: a prescription is a regulatory requirement for the device, so supply and billing records need the prescriber’s order, not just a product name.
  • Product identity: FDA product codes MVA and OAN and HCPCS S1040 are three different identifiers for related things (regulatory category, laser-scan variant, billing description). Mixing them up is an easy way to mislabel a record.
  • Payer criteria: as the crosswalk shows, one plan’s policy includes a repositioning trial and a severity measure that the regulation does not. The FDA indication is not the same thing as coverage, so record which plan policy applies.

Common misunderstandings

  • “It treats any misshapen head.” The FDA indication is nonsynostotic positional plagiocephaly. Head shape differences from craniosynostosis are outside that indication, and the payer policy above excludes them.
  • “It is a protective helmet.” The regulation describes a device that applies pressure to prominent regions of the cranium to improve shape; it is a corrective orthosis, not impact protection.
  • “The evidence is settled.” The guideline grades its recommendations Level II while the only randomized trial found no added value; the guideline itself calls the measurement criteria and timing window elusive.
  • “It works like a splint or collar.” Those are different orthoses with different indications; compare what a splint is and what a cervical collar is.

FAQ

What is a cranial helmet?

It is the common name for a cranial orthosis, a prescription Class II device regulated under 21 CFR 882.5970 that applies pressure to prominent regions of an infant’s cranium to improve cranial symmetry and shape.

Is a cranial helmet a medical device?

Yes. FDA classifies it as a Class II device under product codes MVA and OAN, with special controls for prescription use, biocompatibility testing and labeling.

What ages does the FDA indication cover?

Infants from 3 to 18 months of age with moderate to severe nonsynostotic positional plagiocephaly.

Do you need a prescription?

Yes. The Class II special controls require prescription use in accordance with 21 CFR 801.109.

Is the evidence for cranial helmets settled?

No. The Congress of Neurological Surgeons guideline found a fairly substantive body of non-randomized evidence for faster and greater shape improvement than conservative therapy, while its single randomized trial found no added value. The guideline calls the measurement criteria and the timing window elusive.

Is a cranial helmet a protective or sports helmet?

No. It is a corrective orthosis that applies pressure to prominent regions of an infant’s cranium, not impact protection.

Sources

All sources checked 2026-10-30.

  • 21 CFR 882.5970, Cranial orthosis, via Cornell Legal Information Institute: https://www.law.cornell.edu/cfr/text/21/882.5970
  • openFDA device classification API, regulation number 882.5970 (index updated 2026-10-19): https://api.fda.gov/device/classification.json?search=regulation_number:882.5970
  • Tamber MS et al., Congress of Neurological Surgeons systematic review and evidence-based guideline on cranial molding orthosis (helmet) therapy for positional plagiocephaly, 2016: https://cns.org/Assets/16ca1501-e637-41a5-be54-287209bfba87/636985440887230000/plagiocephalygl-ch-5-orthotic-tx-pdf
  • Geisinger Health Plan, Medical Policy MP125 Cranial Remodeling Orthotic: https://www.geisinger.org/-/media/OneGeisinger/Files/Policy-PDFs/MP/101-150/MP125-Cranial-Remodeling-Orthotic.pdf

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · free to try

Ask about Cranial Helmet: FDA Class, Indications and Evidence

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →